299 related articles for article (PubMed ID: 16586042)
21. Induction of DC-STAMP by alternative activation and downstream signaling mechanisms.
Yagi M; Ninomiya K; Fujita N; Suzuki T; Iwasaki R; Morita K; Hosogane N; Matsuo K; Toyama Y; Suda T; Miyamoto T
J Bone Miner Res; 2007 Jul; 22(7):992-1001. PubMed ID: 17402846
[TBL] [Abstract][Full Text] [Related]
22. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
23. TGFβ1 Regulates Human RANKL-Induced Osteoclastogenesis via Suppression of NFATc1 Expression.
Tokunaga T; Mokuda S; Kohno H; Yukawa K; Kuranobu T; Oi K; Yoshida Y; Hirata S; Sugiyama E
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31991837
[TBL] [Abstract][Full Text] [Related]
24. (-)-Epigallocatechin-3-gallate suppresses osteoclast differentiation and ameliorates experimental arthritis in mice.
Morinobu A; Biao W; Tanaka S; Horiuchi M; Jun L; Tsuji G; Sakai Y; Kurosaka M; Kumagai S
Arthritis Rheum; 2008 Jul; 58(7):2012-8. PubMed ID: 18576345
[TBL] [Abstract][Full Text] [Related]
25. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
[TBL] [Abstract][Full Text] [Related]
26. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
[TBL] [Abstract][Full Text] [Related]
27. Esculetin attenuates receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation through c-Fos/nuclear factor of activated T-cells c1 signaling pathway.
Baek JM; Park SH; Cheon YH; Ahn SJ; Lee MS; Oh J; Kim JY
Biochem Biophys Res Commun; 2015 May; 461(2):334-41. PubMed ID: 25887803
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
29. The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro.
Kawashima M; Fujikawa Y; Itonaga I; Takita C; Tsumura H
Mod Rheumatol; 2009; 19(2):192-8. PubMed ID: 19198759
[TBL] [Abstract][Full Text] [Related]
30. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M
Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680
[TBL] [Abstract][Full Text] [Related]
31. Glycyrrhizae Radix Inhibits Osteoclast Differentiation by Inhibiting c-Fos-Dependent NFATc1 Expression.
Rho TW; Lee SY; Han SY; Kim JH; Lee KH; Kim DS; Kwak HB; Kim YK
Am J Chin Med; 2017; 45(2):283-298. PubMed ID: 28231743
[TBL] [Abstract][Full Text] [Related]
32. Curcumin inhibits osteoclastogenic potential in PBMCs from rheumatoid arthritis patients via the suppression of MAPK/RANK/c-Fos/NFATc1 signaling pathways.
Shang W; Zhao LJ; Dong XL; Zhao ZM; Li J; Zhang BB; Cai H
Mol Med Rep; 2016 Oct; 14(4):3620-6. PubMed ID: 27572279
[TBL] [Abstract][Full Text] [Related]
33. Synovial macrophage-osteoclast differentiation in inflammatory arthritis.
Danks L; Sabokbar A; Gundle R; Athanasou NA
Ann Rheum Dis; 2002 Oct; 61(10):916-21. PubMed ID: 12228163
[TBL] [Abstract][Full Text] [Related]
34. Novel antiosteoclastogenic activity of phloretin antagonizing RANKL-induced osteoclast differentiation of murine macrophages.
Kim JL; Kang MK; Gong JH; Park SH; Han SY; Kang YH
Mol Nutr Food Res; 2012 Aug; 56(8):1223-33. PubMed ID: 22700286
[TBL] [Abstract][Full Text] [Related]
35. Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos.
Grcević D; Lukić IK; Kovacić N; Ivcević S; Katavić V; Marusić A
Clin Exp Immunol; 2006 Oct; 146(1):146-58. PubMed ID: 16968409
[TBL] [Abstract][Full Text] [Related]
36. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
37. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
38. Tanshinone IIA inhibits osteoclast differentiation through down-regulation of c-Fos and NFATc1.
Kwak HB; Yang D; Ha H; Lee JH; Kim HN; Woo ER; Lee S; Kim HH; Lee ZH
Exp Mol Med; 2006 Jun; 38(3):256-64. PubMed ID: 16819284
[TBL] [Abstract][Full Text] [Related]
39. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
40. Gene array identification of osteoclast genes: differential inhibition of osteoclastogenesis by cyclosporin A and granulocyte macrophage colony stimulating factor.
Day CJ; Kim MS; Stephens SR; Simcock WE; Aitken CJ; Nicholson GC; Morrison NA
J Cell Biochem; 2004 Feb; 91(2):303-15. PubMed ID: 14743390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
